tbuckley/cabot-search huggingface dataset:
PWE-094 Understanding The Efficacy of Faecal Microbiota Transplantation in Clostridium Difficile Infection: Re-Establishment of Gut Microbiota with The Ability to Degrade Bile?
Authors: BH Mullish, JAK McDonald, A Pechlivanis, DN Rees, HRT Williams, JR Marchesi, MR Thursz
Journal: Gut (2016)

<h3>Introduction</h3> Faecal microbiota transplantation (FMT) has recently emerged as a highly-effective therapy for recurrent/ refractory <i>Clostridium difficile </i>(recently re-named <i>Peptoclostridium difficile) </i>infection (CDI); however, the specific mechanisms underlying the efficacy of FMT remain largely unclear. Given that different bile salt metabolites differentially affect <i>C. difficile</i>’s ability to germinate and grow both <i>in vitro </i>and <i>in vivo, </i>we hypothesised that CDI is characterised by perturbed bile acid metabolism, and that FMT may exert its efficacy through re-establishment of gut microbiota that restore this process to normal. <h3>Methods</h3> Stool samples were collected from healthy volunteer donors participating in an FMT programme, whilst serial stool samples were collected from a patient successfully treated with FMT for refractory CDI both pre- and post-transplantation. Samples were assayed for structure of the gut microbiota using 16 S rRNA gene sequencing, and for bile acid profiling via liquid chromatography mass spectrometry (LC-MS). Presence of bile salt hydrolases (responsible for deconjugation of glycine- and taurine-conjugated primary bile acids within the gut) was assessed via PCR of bacterial DNA extracted from stool. <h3>Results</h3> A 61 year-old man with refractory CDI was treated with FMT. He demonstrated a modest improvement in diarrhoea after a first FMT, but an immediate, complete and sustained resolution of symptoms after a second FMT from a different donor (performed two weeks after the first). 16 S rRNA gene sequencing demonstrated a pattern of faecal bacterial communities that closely resembled that of the healthy donors by one week after the second FMT. Faecal LC-MS analysis revealed the patient’s gut bile acid profile pre-FMT to be enriched sixfold in taurocholic acid (a potent trigger for <i>C. difficile </i>spore germination <i>in vitro</i>). Post-FMT, the patient’s gut bile acid profile resembled that of healthy donors, with loss of taurocholate and enrichment of secondary bile acids (which are recognised <i>in vitro </i>as inhibitors of <i>C. difficile </i>growth). PCR of bacterial DNA extracted from faeces displayed no detectable BSH genes in the recipient either pre-FMT or by one week following the first FMT, but BSH presence was confirmed in the recipient by one week following the second FMT, as well as in both donors. <h3>Conclusion</h3> FMT may restore bile-degrading members of the gut microbiota, and consequently restore a normal bile acid metabolism to the gut that protects against <i>C. difficile </i>germination. <h3>Disclosure of Interest</h3> None Declared
A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials,
Authors: Ajay K. Nooka, Samatha Muppidi, R. Donald Harvey, Jonathan L. Kaufman, Amelia Langston, Colleen Lewis, Lawrence H. Boise, Christopher R Flowers, Sagar Lonial
Journal: Blood (2011)
OP0189 Rate of Cervical Neoplasia in Systemic Lupus Erythematosus: A Nationwide Cohort-Study: Table 1
Authors: H. Wadström, E.V. Arkema, C. Sjöwall, J. Askling, J.F. Simard
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic lupus erythematosus (SLE) or its treatment might increase the risk of cervical neoplasia as evidenced by previous studies, although inconclusive. Cervical screening can detect subclinical cervical intraepithelial neoplasias and, in turn, offers effective protection against cervical cancer. <h3>Objectives</h3> To examine the risk of cervical neoplasia among women with SLE and across different treatment exposures incorporating findings from cervical screening. <h3>Methods</h3> By linking national Swedish registers we assembled a cohort of women with SLE and matched general population comparators. SLE patients were identified using the National Patient Register. Using the Prescribed drug register, two SLE subcohorts were defined by use of antimalarials and other immune-suppressive treatments (with or without antimalarials). Data on cervical screening came from the Swedish National Cervical Screening Registry, which gathers data on all Pap smears. A composite outcome of cervical dysplasia and invasive cervical cancer during follow-up (2006–2012) was defined using the Cervical Screening Registry and the Swedish Cancer Register. Secondary outcomes considered CIN 1, 2–3, and invasive malignancy separately. Cox models estimated hazard ratios (HR) adjusted for age, sex, education level, healthcare utilization, number of children, marital status, family history of cervical cancer, and prior cervical screening. <h3>Results</h3> Compared to the general population, there was a doubled rate of cervical dysplasia or invasive cancer among women with SLE (HR=2.12 95%CI 1.65–2.71). The rate was higher among those treated with systemic immune-suppressives than among those with only antimalarials (Table). Among women with SLE, immunosuppressive treatment was associated with an increased rate of cervical dysplasia or neoplasms compared to those on antimalarial therapy without additional immunosuppressive treatment (HR=1.83 95% CI 1.15–2.91). Results were generally similar for the secondary outcomes, however limited due to number of events and follow-up time, particularly in the antimalarial treated group. <h3>Conclusions</h3> SLE is a risk factor for cervical neoplasia, even after adjusting for important risk determinants such as previous cervical screening. The clinical implication of our findings is that SLE patients treated with immune-suppressives are at increased risk of cervical neoplasia and should be adequately monitored, regardless of whether the risk increase is due to disease severity or treatment. <h3>Disclosure of Interest</h3> None declared
AB0785 Relationship between Metabolic Syndrome and Its Components with Bone Density in Menopause Women
Authors: M. Abbasi, Z. Yazdi, S.A. Farzam, Z. Mamaghani
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Prevention of osteoporosis and bone fracture and the relationship between metabolic syndrome and bone density are controversial issues. <h3>Objectives</h3> The present study aimed to investigate metabolic syndrome and its components and the association with bone mineral density in post menopausal women referring for bone mineral density (BMD) test. <h3>Methods</h3> A total of 143 postmenopausal women with at least one year of menopause experience participated in this cross-sectional study. Demographic and anthropometric characteristics for all participants were collected. Biochemical parameters including fasting blood sugar, Cholesterol (HDL and LDL), triglyceride were also measured prior to BMD test. Afterwards, association between the components of metabolic syndrome and bone densitometry were analyzed using statistical methods. <h3>Results</h3> In this study, 72% of participants did not have metabolic syndrome. Among them, 43.4% and 28.7% had osteoporosis and normal density, respectively. Of the remaining28% with metabolic syndrome 12.6% had osteoporosis and 15.4% had normal density. Among the metabolic syndrome components, waist circumference, HDL cholesterol, and waist to hip ratio were found to be significantly associated with bone mass (P&lt;0.05). Osteoporotic women had lower waist circumference and waist to hip ratio and higher HDL than women without osteoporosis. In contrast, women with metabolic syndrome did not have significant differences with women without metabolic syndrome in terms of lumbar and femoral neck densitometry (P&gt;0.05). <h3>Conclusions</h3> Results from this study showed that metabolic syndrome and its components did not induce bone mass loss. Due to discrepancies of the studies in this area, it seems that more studies are needed so as to make it possible to take some preventive measures in large scale. <h3>References</h3> Nayak B, Pinto Pereira L, Seemungal T, Davis G, Teelucksingh S, Jagessar A, et al. Relationship of fasting total homocysteine, high sensitivity C-reactive protein and features of the metabolic syndrome in Trinidadian subjects. Archives of physiology and biochemistry. 2013;119(1):22–6. Demirtas RN, Ozel CB, Arikan H, Calik-Kutukcu E, Saglam M, Vardar-Yagli N, et al. C-reactive protein: Its correlations with pulmonary function, physical capacity and anthropometric measurements in patients with metabolic syndrome. European Respiratory Journal. 2014;44(Suppl 58):P4326. <h3>Acknowledgement</h3> The authors gratefully acknowledge the cooperation of the study participants. We thank the subject volunteers and subject involved in data collection <h3>Disclosure of Interest</h3> None declared
AB0284 Reproductive Health in Adult Women with JIA and RA:
Authors: M.E.B. Clowse, G. McDaniel
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Building a family is an important part of a full life for many women with rheumatoid arthritis (RA) and juvenile inflammatory arthritis (JIA). <h3>Objectives</h3> Our goal was to identify the differences and similarities between the reproductive health choices and practices of women with RA and JIA. <h3>Methods</h3> A cross-sectional survey was completed by women between age 18–39 with a diagnosis of RA and/or JIA seen in a university rheumatology clinic. Descriptive statistical methods were used. <h3>Results</h3> Of the 33 women that completed the survey, 22 were diagnosed with RA at or after age 18 and 11 were diagnosed with JIA. The average age at diagnosis and the time of the survey was higher for women with RA (see table). The majority of participants were white. Methotrexate (MTX) had been used by all women with JIA and 73% of women with RA. The average total lifetime dose and duration of MTX dose was significantly higher among women with JIA. Contraception: 4 women with RA were trying to conceive at the time of the survey. Among the other women, the rates of effective contraceptive use was similar, but more women with RA used an IUD or surgery and more women with JIA were taking daily birth control pills. Pregnancy: Women in both groups reported a similar ideal number of children. About 2/3 of the women had either tried to conceive or been pregnant. The average age of first attempted pregnancy was similar between women with RA and JIA. Of the women who had tried to conceive or been pregnant, both groups had a similar number of pregnancies and the rates of live births, miscarriages, ectopic pregnancies, and elective terminations were not significantly different between the groups. Fertility: Of the women who tried to get pregnant or had a pregnancy, 19% with RA and 40% with JIA reported infertility (p=0.3) and 12.5% with RA and 60% with JIA had used a fertility treatment to attempt pregnancy (p=0.03). The age of menarche, the frequency of menstrual irregularities, and the number of menses per year were similar between the groups. <h3>Conclusions</h3> The reproductive goals of women with JIA and RA appear to be similar. The majority of sexually active women were using effective contraception, with women with RA using long-acting options and women with JIA relying on birth control pills. Pregnancy outcomes appeared to be similar. Infertility was increased, particularly among women with JIA. <h3>Disclosure of Interest</h3> M. Clowse Grant/research support from: Pfizer, G. McDaniel Grant/research support from: Pfizer
A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,
Authors: Ian W. Flinn, William N. Harwin, Inés M. Macias-Pérez, Patrick S. Tucker, David M. Waterhouse, Steven W. Papish, Jeffrey A. Jones, John D. Hainsworth, John C. Byrd
Journal: Blood (2011)
AB0576 Ophtalmologic Findings in Patients with Takayasu's Arteritis: Table 1.
Authors: A.B. Kelesoglu, A. Baytaroglu, A. Sari, A. Erden, L. Kilic, O. Tatar, O. Karadag, U. Kalyoncu, I. Ertenli, S. Apras Bilgen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Takayasu9s Arteritis (TA) is a large vessel vasculitis of young females. Ophtalmologic findings as wreath-like arteriovenous anastomosis around the optic disc are the firstly described clues for TA. Opthalmologic pathologies could have negative impact on quality of life but, there are limited data about ocular manifestations of TA. <h3>Objectives</h3> To investigate the ophthalmologic manifestations of TA. <h3>Methods</h3> In this cross-sectional study 33 TA (F/M: 29/4) patients were evaluated. Demographic and clinical findings were recorded from hospital files. Addition to routine examination, anterior segment and fundus of eyes were assessed. <h3>Results</h3> The median age at the time of ocular examination was 38 (min-max:19–62) years and mean disease duration was 5.7±5.5 years. Two (6.1%) patients had diabetes mellitus, 13 (39.4%) patients had hypertension. Only one patient had cranial involvement of TA. Most of the patients had been taking immunosuppressive agents addition to corticosteroids [Methotrexate (n=11, (33.3%)), cyclophosphamide (n=9, (27.3%)), azathiopurine (n=5, (15.2%)), one patient for each mycophenolate mophetil, infliximab, tocilizumab] Of patients 15 (45.4%) had pathologic findings in opthalmologic examinations. Twelve patients (36.4%) had anterior segment pathology, 10 (30.3%) patients had posterior segment pathology. Of these patients 7 (21.2%) had both anterior and posterior segment pathology. Distribution of anterior segment pathologies were; 9 (27.2%) patients had cataract, 2 (6.1%) patients had dry eyes and one patient had congenital disgenesis. In fundoscopic examination of posterior segment, hypertensive retinopathy was the most frequent pathologic finding as 12.1% (n=4) Three of these patients have had diagnosis of essential hypertension and were treated with anti-hypertensive medication One patient had ocular ischemic syndrome which is typical for TA (Table 1). <h3>Conclusions</h3> In the early results of our study, disease or treatment related ocular pathologic findings were frequent in TA. Periodic consultation and ophthalmologic examination of TA patients might be rational approach in follow up of these patients. <h3>Disclosure of Interest</h3> None declared
SAT0242 Lung Involvement in Undifferentiated Connective Tissue Diseases (UCTD): Relationship with Clinical and Capillaroscopic Features
Authors: R. Irace, A. Riccardi, S. Vettori, M. Iudici, G. Valentini
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with UCTD (1) have been reported to present lung involvement most frequently characterized by nonspecific interstitial pneumonia (NSIP) at High Resolution Computerized Assial Tomography (HR-CAT), FVC and DLCO values lower than predicted (2). <h3>Objectives</h3> To investigate UCTD patients for the presence of lung involvement and search for demographic, serological, capillaroscopic and organ involvement features associated with it. <h3>Methods</h3> Eighty-six patients consecutively admitted to the Rheumatology Unit of the Second University of Naples and satisfying criteria for the classification of UCTD (1) were enrolled into the study. Patients presenting with any major CTD marker autoantibody other than anti-Ro (SSA) and/or scleroderma capillaroscopic specific pattern were excluded. Each patient underwent a careful history, a complete physical examination, evaluation of serum Antinuclear (ANA) and anti Extraible Nuclear Antigens antibody (anti-ENA), videocapillaroscopy, echo-Doppler-cardiography with evaluation of Left ventricular E/A ratio. Those who consented also underwent HR-CAT and esophagotonometry. Interstitial lung disease (ILD) was defined by HR-CAT or, if unavailable, by FVC&lt;80% plus DLCO&lt;80%. <h3>Results</h3> The table lists the features detected in the patients subdivided according to the presence of lung involvement. DLCO &lt;80% was found in 30/86 (34.8%) patients; FVC &lt;80% in 3/86 (1.2%); HR-CAT was carried in 36/86 (41.8%) patients. It pointed a lung involvement NSIP pattern in 5/36 patients (13%). An isolated reduction of DLCO resulted the be the most frequent finding and might depend on pulmonary vascular disease. Anti-SSA positivity and Capillaroscopic alterations were detected more frequently in patients with lung involvement (either isolated reduction of DLCO or ILD). <h3>Conclusions</h3> We detected a prevalence of ILD in UCTD lower than previously reported (2) (80%). Nevertheless, we found an isolated reduction of DLCO in about 35% of the UCTD patients. Lung involvement resulted to be significantly associated with capillaroscopic alterations and anti-SSA positivity. <h3>References</h3> Mosca M, Tani C, Vagnani S, Carli L, Bombardieri S.The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun. 2014;48–49:50–2 Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, Jones KD, King TE Jr. Am J Respir Crit Care Med. Oct 1;176(7):691–7 <h3>Disclosure of Interest</h3> None declared
Sequential Evaluation of the Proportion of Granulocyte JAK2 (V617F) Mutant Alleles in Chronic Myeloproliferative Disorders.
Authors: Francesco Passamonti, Elisa Rumi, Daniela Pietra, Chiara Elena, Luca Arcaini, Emanuela Boveri, Cristiana Pascutto, Mario Lazzarino, Mario Cazzola
Journal: Blood (2006)
JAK2V617F-Mediated Phosphorylation of PRMT5 Down-Regulates Its Methyltransferase Activity and Promotes Myeloproliferation
Authors: Fan Liu, Xinyang Zhao, Fabiana Perna, Lan Wang, Priya Koppikar, Omar Abdel-Wahab, Ross L Levine, Hao Xue, Megan Hatlen, Silvia Menendez, Stephen D Nimer
Journal: Blood (2010)
Novel Predictor Of Lenalidomide Response In Non-del5q MDS Reveals Linkage To Molecular Mechanism: First Characterization Of T-Cell Function In Cereblon Homozygous Deficient Mice
Authors: Pearlie K Epling-Burnette, Ying Han, Adam W Mailloux, Ling Zhang, Jessica M. McDaniel, Rajadhyaksha Anjali, Sheng Wei, Ritchie David, Paul Neeson, Rami S. Komrokji, Alan List
Journal: Blood (2013)
Prevalence of Thrombophilia Genes in Patients with Idiopathic Thromboembolic Disease.
Authors: Eudokia Mandala, Christos Lafaras, Theodoros Dardavesis, Mattheos Speletas, Dimitrios Platogiannis, Constantina Tsioni, Eudoxia Douvleti, George Ilonidis
Journal: Blood (2007)
AB0706 Lipid Profile and Active Systemic Inflammation May Differently Affect The Pathomechanism of Cardiovascular Disorders in Ankylosing Spondylitis (AS) and in Psoriatic Arthritis (PSA)
Authors: P. Gluszko, K. Bonek, R. Rupinski, J. Wronski, W. Maslinski
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To investigate lipid profile, inflammatory mediators, markers of endothelial activation and other clinical factors associated with cardiovascular risk in AS and PsA. <h3>Methods</h3> Lipid profile, atherogenic index (AI –the TC: HDL)), CRP level, disease activity (BASDAI and ASDAS), patients BMI and risk factors like smoking and hypertension were evaluated in 21 AS patients (6 female, 15 male, mean age 41,6±7,4 years, with disease duration of 6,5 ±10,1 years) and in 18 PsA patients (8/f, 10/m, mean age 46,1± 10,6 y., disease duration 6.1±7,5 y.). Serum concentrations of ICAM-1, RANTES, CD40 Ligand were measured using ELISA. The SCORE calculator was used for CV risk estimation. <h3>Results</h3> Mean values of BMI for AS and PsA patients, mean age and the disease duration did not differ significantly between the study groups. There were 9 smokers, 6 patients with hypertention and 3 patients with a coronary heart disease (CHD) in AS group and 5 smokers, 11 patients with hypertension, 3 with CHD in PsA. Mean values of BASDAI 5,9±1,9 SD in AS and 4,4±2,2 in PsA indicated active diseases. The SCORE CV risk above 5% was found in 4 patients (19%) with AS and in 3 PsA patients (16%). In AS AI (3.6±1) was significantly lower and HDL/LDL (0.51 ±0,1) higher vs. AI (4,4±1) and HDL/LDL (0,46± 0,1) in PsA (p&lt;0,03). 14 (AS + PsA) smokers revealed higher serum levels of ICAM-1 (17,9± 7,7 ng/ml) comparing to 25 non –smokers (12,8±2,5 p=0.004). In AS we found significant (p&lt;0,05) positive correlations between BASDAI values and HDL levels (r=0,4) and ASDAS and HDL (r=0,55) and negative correlations between BASDAI and AI (r= -0,60), ASDAS and AI (r= -0,50), BASDAI and CD 40 Ligand (r= -0,5). In PsA only BASDAI positively correlated with HDL levels (r=0,56). In non –smokers AI positively correlated with CD40 Ligand and CD40 Ligand negatively correlated with BASDAI. In smokers BASDAI and ASDAS positively correlated with HDL and BASDAI negatively with AI. We did not find any correlatinons between SCORE risk, disease activity, markers of inflammation and vascular injury. <h3>Conclusions</h3> In our opinion the SCORE calculator underestimates CV risk in AS and PsA. Higher activity of the disease is associated with elevated HDL levels and decreased AI (a lipid paradox), which may suggest, that mostly in active AS, factors other then cholesterol-related are associated with the pathogenesis of CV disorders. Neither lipid alterations nor inflammatory mediators but smoking seems to be the strongest factor associated with a direct vascular injury. <h3>Disclosure of Interest</h3> None declared